Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.

...
more >
Materials for 24 May 2017 Annual Meeting
  • Agenda & Resolutions FR | ENG
  • Board report on extraordinary resolutions FR | ENG
  • CV of proposed board member ENG
  • Lettre aux actionnaires FR
  • Comptes annuels FR
  • IFRS consolidated financial statements FR | ENG
  • 2016 Annual Report ENG
  • Auditors Report on IFRS Accounts ENG
  • Auditors report on AAA S.A. accounts FR
  • Auditors report on AAA S.A. related party transactions FR
Latest Newsmore >
05/31/17
Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017
On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 NETSPOT® Unit Sales per Month Jump 140% During First Quarter First Quarter 2017 Highlights: Advanced preparations for resubmission of lutetium Lu 177 dotatate (Lutathera®) New Drug Application to FDA Results of Phase 3 NETTER-1 study of investigational drug lutetium Lu 177 dotatate (Lutathera®) published in The New England Journal of Medicine Enhanced supply chain for lutetium 177-labeled product... 
05/30/17
Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer
SAINT-GENIS-POUILLY, France and OXFORD, UK, May 30, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA), an international specialist in Molecular Nuclear Medicine, and Blue Earth Diagnostics Ltd., a molecular imaging diagnostics company, today announced that they have entered into a non-exclusive manufacturing agreement and an exclusive distribution agreement for the supply of Blue Earth Diagnostics’ PET imaging product Axumin™ (fluciclovine (18F)) in France, Ge... 
05/25/17
Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors
SAINT-GENIS-POUILLY, France, May 25, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that Christine Mikail, J.D. has joined the Company’s board of directors as an independent non-executive director. “Ms. Mikail brings both a broad legal skillset and substantial business development experience in the pharmaceutical industry,” stated Stefano Buono, Chief Executi... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources